FrancophonIA/ELRC3.0 huggingface dataset:
English: In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or Angiotensin II antagonist and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure,which is usually reversible.
Slovenian: Pri nekaterih bolnikih z zmanjšano ledvično funkcijo (npr. dehidriranih bolnikih ali starejših bolnikih z zmanjšano ledvično funkcijo) lahko sočasno jemanje zaviralca ACE ali zaviralca receptorjev angiotenzina II in učinkovin, ki zavirajo ciklooksigenazo, povzroči nadaljnje poslabšanje ledvične funkcije, vključno z možno akutno ledvično odpovedjo, kar pa je ponavadi reverzibilno.
English: Cardiovascular data:
Slovenian: Srčno-žilni podatki:
English: Etoricoxib, as with other medicinal products inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester.
Slovenian: Etorikoksib, tako kot druga zdravila, ki zavirajo tvorbo prostaglandinov, lahko povzroči inertnost maternice in prezgodnje zaprtje Botallovega voda (ductus arteriosus) v zadnjem tromesečju.
English: Common: dizziness, headache.
Slovenian: Pogoste: omotica, glavobol.
English: The rates for confirmed upper gastrointestinal perforations, ulcerations and bleeds were the same for etoricoxib and diclofenac (1.11 events per 100 patient years.)
Slovenian: Deleži potrjenih perforacij, razjed in krvavitev zgornjih prebavil so bili pri etorikoksibu in diklofenaku enaki (1,11 dogodka na 100 bolnikov-let).
English: This interaction may result in recurrence of symptoms when etoricoxib is co-administered with rifampicin.
Slovenian: Ta interakcija lahko povzroči ponovni pojav simptomov pri sočasni uporabi etorikoksiba in rifampicina.
English: The effects of etoricoxib 120 mg on the exposure (AUC0-24hr) to these estrogenic components of PREMARIN <or local TRADEMARK> were less than half of those observed when PREMARIN <or local TRADEMARK> was administered alone and the dose was increased from 0.625 to 1.25 mg.
Slovenian: Učinki etorikoksiba 120 mg na izpostavitev (AUC0-24hr) tem estrogenskim sestavinam zdravila PREMARIN <ali lokalna BLAGOVNA ZNAMKA> so bili manj kot polovični v primerjavi z učinki pri jemanju samo zdravila PREMARIN <ali lokalna BLAGOVNA ZNAMKA>, če so odmerek povečali z 0,625 mg na 1,25 mg.
English: Cardiac disorders: Uncommon: congestive heart failure, non-specific ECG changes, myocardial infarction
Slovenian: Srčne bolezni: Občasne: kongestivno srčno popuščanje, nespecifične spremembe EKG, miokardni infarkt
English: Etoricoxib is excreted in the milk of lactating rats at concentrations approximately two-fold those in plasma.
Slovenian: Etorikoksib se izloča v materino mleko podgan v koncentracijah, ki so približno dvakratnik koncentracij v plazmi.
English: Rifampicin: Co-administration of etoricoxib with rifampicin, a potent inducer of CYP enzymes, produced a 65% decrease in etoricoxib plasma concentrations.
Slovenian: Rifampicin: Pri sočasnem jemanju etorikoksiba in rifampicina, močnega induktorja encimov CYP, se je plazemska koncentracija etorikoksiba zmanjšala za 65 %.
English: Tablet coating: Carnauba wax, lactose monohydrate, hypromellose, titanium dioxide (E171), glycerol triacetate.
Slovenian: Obloga tablete: karnauba vosek, laktoza monohidrat, hipromeloza, titanov dioksid (E 171), gliceriltriacetat.
English: The event rates for serious thrombotic events were: Etoricoxib 1.25 events per 100 patient years versus 1.15 events per 100 patient years for diclofenac (relative risk 1.07;95% CI: 0.65%, 1.74%).
Slovenian: Deleža resnih trombotičnih dogodkov sta bila: pri etorikoksibu 1,25 dogodka na 100 bolnikov-let, pri diklofenaku pa 1,15 dogodka na 100 bolnikov-let (relativno tveganje 1,07, 95 % interval zaupanja: 0,65 %, 1,74 %).
English: Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.
Slovenian: Potrjena ishemična srčna bolezen, bolezen perifernih arterij in/ali cerebrovaskularna bolezen.
English: The 60- and 120-mg tablets also contain indigo carmine lake (E132) and yellow ferric oxide (E172).
Slovenian: 60 mg in 120 mg tablete vsebujejo še indigo karmin (E 132) in rumeni železov oksid (E 172).
English: COX-2 has been identified in tissue around gastric ulcers in man but its relevance to ulcer healing has not been established.
Slovenian: COX-2 so odkrili v tkivu okoli želodčnih razjed pri človeku, vendar njenega pomena pri celjenju razjed še niso dokazali.
English: COX-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effect.
Slovenian: Selektivni zaviralci COX-2 pri preprečevanju srčno-žilnih tromboembolijskih bolezni niso nadomestilo za acetilsalicilno kislino, ker nimajo antiagregacijskega učinka.
English: All active comparators showed an increase relative to placebo with respect to systolic blood pressures; however, etoricoxib was associated with a statistically significant increase at Day 14 when compared to celecoxib and naproxen (mean change from baseline for systolic blood pressure: etoricoxib 7.7 mmHg, celecoxib 2.4 mmHg, naproxen 3.6 mmHg).
Slovenian: Vsa preučevana zdravila so v primerjavi s placebom zvišala sistolični krvni tlak, pri tem pa je bil etorikoksib v primerjavi s celekoksibom in naproksenom povezan s statistično pomembnim zvišanjem krvnega tlaka 14. dan zdravljenja (povprečna sprememba glede na izhodiščno vrednost sistoličnega krvnega tlaka: etorikoksib 7,7 mmHg, celekoksib 2,4 mmHg, naproksen 3,6 mmHg).
English: Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids, coxibs
Slovenian: Farmakoterapevtska skupina: Nesteroidni protivnetni in protirevmatični pripravki, koksibi
English: If a woman becomes pregnant during treatment, etoricoxib should be discontinued.
Slovenian: Če ženska zanosi tekom zdravljenja, je treba etorikoksib ukiniti.
English: Etoricoxib is approximately 92% bound to human plasma protein over the range of concentrations of 0.05 to 5 µg/ml.
Slovenian: Približno 92 % etorikoksiba se pri ljudeh v koncentracijah 0,05 do 5 µg/ml veže na plazemske beljakovine.
English: The principal metabolite is the 6'-carboxylic acid derivative of etoricoxib formed by further oxidation of the 6'-hydroxymethyl derivative.
Slovenian: Glavni presnovek je 6'-karboksilni derivat etorikoksiba, ki nastane z nadaljnjo oksidacijo 6'-hidroksimetil presnovka.
English: Very rare: peptic ulcers including gastrointestinal perforation and bleeding (mainly in the elderly).
Slovenian: Zelo redke: razjede v želodcu, vključno s perforacijami in krvavitvami v prebavilih (večinoma pri starejših bolnikih).
English: Some selective COX-2 inhibitors have been associated with an increased risk of skin reactions in patients with a history of any drug allergy.
Slovenian: Nekateri selektivni zaviralci COX-2 so bili povezani s povečanim tveganjem za neželene učinke na koži pri bolnikih, ki so v preteklosti imeli alergijo na katerokoli zdravilo.
English: A significant difference in GI safety between selective COX-2 inhibitors + acetylsalicylic acid vs. NSAIDs + acetylsalicylic acid has not been demonstrated in long-term clinical trials (see section 5.1).
Slovenian: Pomembne razlike v varnosti za prebavila med zdravljenjem s selektivnimi COX-2 zaviralci in acetilsalicilno kislino ter zdravljenjem z NSAR-i in acetilsalicilno kislino v dolgoročnih kliničnih raziskavah niso dokazali (glejte poglavje 5.1).
English: Elimination of etoricoxib occurs almost exclusively through metabolism followed by renal excretion.
Slovenian: Izločanje etorikoksiba poteka skoraj izključno s presnavljanjem, ki mu sledi izločanje skozi ledvice.
English: In a pharmacokinetic study (n=16) conducted in adolescents (aged 12 to 17) the pharmacokinetics in adolescents weighing 40 to 60 kg given etoricoxib 60 mg once daily and adolescents >60 kg given etoricoxib 90 mg once daily were similar to the pharmacokinetics in adults given etoricoxib 90 mg once daily.
Slovenian: V farmakokinetični raziskavi (n = 16) pri mladostnikih (starih 12 do 17 let) je bila farmakokinetika pri mladostnikih s telesno težo 40 do 60 kg, ki so dobivali etorikoksib 60 mg enkrat na dan, in mladostnikih s telesno težo > 60 kg, ki so dobivali etorikoksib 90 mg enkrat na dan, podobna farmakokinetiki pri odraslih, ki so dobivali 90 mg etorikoksiba enkrat na dan.
English: Infections and infestations: Uncommon: gastroenteritis, upper respiratory infection, urinary tract infection.
Slovenian: Infekcijske in parazitske bolezni: Občasne: gastroenteritis, okužbe zgornjih dihal, okužbe urinarnih poti.
English: However, concomitant administration of low-dose acetylsalicylic acid with etoricoxib may result in an increased rate of GI ulceration or other complications compared to use of etoricoxib alone.
Slovenian: Vendar se lahko pri sočasni uporabi majhnih odmerkov acetilsalicilne kisline in etorikoksiba pojavi večje število ulceracij v prebavilih in drugih zapletov kot pri zdravljenju z etorikoksibom samim.
English: These interactions should be considered in patients taking etoricoxib concomitantly with ACE inhibitors or angiotensin II antagonists.
Slovenian: Te interakcije je treba upoštevati pri bolnikih, ki jemljejo etorikoksib sočasno z zaviralci ACE ali zaviralci receptorjev angiotenzina II.
English: The clinical relevance of these observations has not been established.
Slovenian: Klinične pomembnosti tega odkritja niso dokazali.
English: In rats and rabbits, no embryo/foetal effects were seen at systemic exposures equal to or less than those at the daily human dose [90 mg].
Slovenian: Pri podganah in kuncih niso ugotovili vpliva na zarodek/plod pri sistemski izpostavitvi, enaki ali manjši od priporočenega dnevnega odmerka pri človeku (90 mg).
English: - Addition of the contraindications Established ischaemic heart disease and/or cerebrovascular disease and Peripheral arterial disease.
Slovenian: - Dodani sta kontraindikaciji Potrjena ishemična srčna bolezen in/ali cerebrovaskularno obolenje ter Periferna arterijska bolezen.
English: - Addition of a warning for prescribers to exercise caution when prescribing NSAIDs, in combination with ACE inhibitors or angiotensin II receptor antagonists.
Slovenian: - Dodano je opozorilo, da je potrebna previdnost pri predpisovanju nesteroidnih antirevmatikov v kombinaciji z zaviralci ACE ali antagonisti receptorjev angiotensina II.
English: The following undesirable effects were reported at an incidence greater than placebo in clinical trials in patients with OA, RA or chronic low back pain treated with etoricoxib 60 mg or 90 mg for up to 12 weeks or in post-marketing experience:
Slovenian: O naslednjih neželenih učinkih, katerih pojavnost je bila večja kot pri placebu, so poročali v kliničnih raziskavah pri bolnikih z OA, RA ali kronično bolečino v križu, ki so se z etorikoksibom v odmerkih 60 mg ali 90 mg zdravili do 12 tednov:
English: Rats developed hepatocellular and thyroid follicular cell adenomas at >2-times the daily human dose [90 mg] based on systemic exposure when dosed daily for approximately two years.
Slovenian: Pri podganah so se pojavili hepatocelularni adenomi in folikularni adenomi ščitnice pri > 2-kratnem dnevnem odmerku za človeka (90 mg) glede na sistemsko izpostavitev pri dnevnem odmerjanju približno dve leti.
English: History of hypersensitivity to the active substance or to any of the excipients (see section 6.1).
Slovenian: Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov (glejte 6.1) v preteklosti.
English: Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid concomitantly or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding.
Slovenian: Previdnost priporočamo pri zdravljenju bolnikov z največjim tveganjem za nastanek zapletov v prebavilih pri NSAR-ih: starejših bolnikih, bolnikih, ki sočasno jemljejo katerikoli drug NSAR ali acetilsalicilno kislino ali bolnikih, ki so kdaj imeli bolezni prebavil, kot je razjeda ali krvavitev v prebavilih.
English: However, patients who experience dizziness, vertigo or somnolence while taking etoricoxib should refrain from driving or operating machinery.
Slovenian: Bolniki, ki med jemanjem etorikoksiba občutijo omotico, vrtoglavico ali zaspanost, morajo opustiti vožnjo ali upravljanje strojev.
English: In clinical trials for acute gouty arthritis, etoricoxib was given for 8 days.
Slovenian: V kliničnih raziskavah akutnega uričnega artritisa so bolniki etorikoksib prejemali 8 dni.
English: In dogs, renal and gastrointestinal abnormalities were seen at high exposures.
Slovenian: Pri psih so nenormalnosti ledvic in prebavil opazili pri velikih izpostavitvah.
English: Orally administered etoricoxib is well absorbed.
Slovenian: Peroralno zaužiti etorikoksib se dobro absorbira.
English: In the 14-week toxicity study etoricoxib caused gastrointestinal ulcers at exposures greater than those seen in man at the therapeutic dose.
Slovenian: V 14-tedenski raziskavi toksičnosti je etorikoksib povzročil razjede v prebavilih pri izpostavitvah, večjih od tistih pri človeku pri terapevtskem odmerku.
English: Following 120 mg once-daily dosing to steady state, the peak plasma concentration (geometric mean Cmax = 3.6 µg/ml) was observed at approximately 1 hour (Tmax) after administration to fasted adults.
Slovenian: Po odmerjanju 120 mg enkrat na dan do stanja dinamičnega ravnovesja so maksimalno plazemsko koncentracijo (geometrična sredina Cmax = 3,6 µg/ml) pri odraslem izmerili približno eno uro (Tmax) po zaužitju na tešče.
English: Core: Calcium hydrogen phosphate (anhydrous), croscarmellose sodium, magnesium stearate, microcrystalline cellulose.
Slovenian: Jedro: kalcijev hidrogenfosfat (brezvoden), premrežen natrijev karmelozat, magnezijev stearat, mikrokristalna celuloza.
English: No clinical data on exposed pregnancies are available for etoricoxib.
Slovenian: Med obdobjem nosečnosti za etorikoksib ni na voljo nobenih kliničnih podatkov.
English: ANNEX IV CONDITIONS OF THE MARKETING AUTHORISATION
Slovenian: DODATEK IV POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM
English: Etoricoxib is extensively metabolised with <1% of a dose recovered in urine as the parent drug.
Slovenian: Etorikoksib se močno presnavlja, < 1 % odmerka se pojavi v urinu v obliki prvotne učinkovine.
English: Effect of etoricoxib on drugs metabolised by sulfotransferases
Slovenian: Vpliv etorikoksiba na zdravila, ki jih presnavljajo sulfotransferaze
English: Renal insufficiency: No dosage adjustment is necessary for patients with creatinine clearance ≥30 ml/min (see section 5.2).
Slovenian: Ledvična okvara: Pri bolnikih s kreatininskim očistkom ≥ 30 ml/min prilagajanje odmerkov ni potrebno (glejte 5.2).
English: There were no statistically significant differences between etoricoxib and placebo.
Slovenian: Med etorikoksibom in placebom ni bilo statistično značilne razlike.
English: The main pathway of etoricoxib metabolism is dependent on CYP enzymes.
Slovenian: Glavna pot presnove etorikoksiba je odvisna od encimov CYP.
English: Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with etoricoxib after careful consideration (see section
Slovenian: Bolnike s pomembnimi dejavniki tveganja srčno-žilnih dogodkov (npr. visok krvni tlak, hiperlipidemija, sladkorna bolezen, kajenje) lahko z etorikoksibom zdravimo le po skrbnem premisleku (glejte poglavje 5.1).
English: In one study, etoricoxib 120 mg had no effect, but in the other study, etoricoxib 120 mg increased methotrexate plasma concentrations by 28% and reduced renal clearance of methotrexate by 13%.
Slovenian: V eni od raziskav etorikoksib v odmerku 120 mg ni vplival na plazemske koncentracije metotreksata ali ledvični očistek, v drugi raziskavi pa je povečal plazemske koncentracije metotreksata za 28 % in zmanjšal ledvični očistek metotreksata za 13 %.
English: In vitro studies indicate that CYP2D6, CYP2C9, CYP1A2 and CYP2C19 also can catalyse the main metabolic pathway, but their quantitative roles in vivo have not been studied.
Slovenian: In vitro raziskave nakazujejo, da lahko tudi CYP2D6, CYP2C9, CYP1A2 in CYP2C19 katalizirajo glavno presnovno pot, vendar njihove kvantitativne vloge niso preučevali in vivo.
English: Renal prostaglandins may play a compensatory role in the maintenance of renal perfusion.
Slovenian: Ledvični prostaglandini imajo lahko kompenzatorno vlogo pri vzdrževanju prekrvavitve ledvic.
English: Therefore, under conditions of compromised renal perfusion, administration of etoricoxib may cause a reduction in prostaglandin formation and, secondarily, in renal blood flow, and thereby impair renal function.
Slovenian: Zato lahko pri stanjih z zmanjšano prekrvavitvijo ledvic jemanje etorikoksiba zmanjša tvorbo prostaglandinov ter posledično zmanjša pretok krvi skozi ledvice in tako okvari ledvično funkcijo.
English: Renal insufficiency: The pharmacokinetics of a single dose of etoricoxib 120 mg in patients with moderate to severe renal insufficiency and patients with end-stage renal disease on hemodialysis were not significantly different from those in healthy subjects.
Slovenian: Ledvična okvara: Farmakokinetika enkratnega odmerka 120 mg etorikoksiba pri bolnikih z zmerno do hudo ledvično okvaro ter pri bolnikih s končno ledvično odpovedjo na hemodializi, se ni pomembno razlikovala od farmakokinetike pri zdravih preiskovancih.
English: There is a further increase in the risk of gastrointestinal adverse effects (gastrointestinal ulceration or other gastrointestinal complications) when etoricoxib is taken concomitantly with acetylsalicylic acid (even at low doses).
Slovenian: Tveganje za neželene učinke v prebavilih (razjede ali drugi zapleti v prebavilih) se dodatno poveča pri jemanju etorikoksiba sočasno z acetilsalicilno kislino (celo v majhnih odmerkih).
English: The clinical significance of these increases is unknown, and higher doses of PREMARIN <or local TRADEMARK> were not studied in combination with etoricoxib.
Slovenian: Večjih odmerkov zdravila PREMARIN <ali lokalna BLAGOVNA ZNAMKA> v kombinaciji z etorikoksibom niso preučili.
English: In clinical trials, etoricoxib was administered without regard to food intake.
Slovenian: V kliničnih raziskavah se je etorikoksib uporabljal ne glede na vnos hrane.
English: The use of etoricoxib, as with any drug substance known to inhibit COX-2, is not recommended in women attempting to conceive.
Slovenian: Uporabe etorikoksiba, tako kot uporabe drugih zdravil, ki zavirajo COX-2, pri ženskah, ki nameravajo zanositi, ne priporočamo.
English: On 7 April 2005, the FDA (Food and Drug Administration) and the EMEA requested that Pfizer voluntarily withdraw Bextra (valdecoxib) from the market and Pfizer agreed to suspend sale and marketing of Bextra worldwide pending further discussions on the unfavorable risk versus benefit due to data on serious skin reactions.
Slovenian: Dne 7. aprila 2005 sta FDA (Food and Drug Administration) in EMEA zaradi podatkov o hudih kožnih reakcijah zahtevali, da podjetje Pfizer prostovoljno umakne zdravilo Bextra (valdekoksib) iz prometa.
English: Any patients with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver function test has occurred, should be monitored.
Slovenian: Spremljati moramo vsakega bolnika, ki ima simptome in/ali znake, ki kažejo na moteno delovanje jeter, ali nenormalne teste jetrne funkcije.
English: Across clinical pharmacology studies, <INVENTED NAME> produced dose-dependent inhibition of COX-2 without inhibition of COX-1 at doses up to 150 mg daily.
Slovenian: V kliničnih farmakoloških raziskavah je imela < IZMIŠLJENO IME > v odmerkih do 150 mg dnevno od odmerka odvisen zaviralni učinek na COX-2, ne da bi zavirala COX-1.
English: Acetylsalicylic Acid: In a study in healthy subjects, at steady state, etoricoxib 120 mg once daily had no effect on the anti-platelet activity of acetylsalicylic acid (81 mg once daily).
Slovenian: Acetilsalicilna kislina: V raziskavi pri zdravih preiskovancih v stanju dinamičnega ravnovesja etorikoksib v odmerku 120 mg enkrat na dan ni vplival na antiagregacijski učinek acetilsalicilne kisline (81 mg dnevno).
English: Pharmacodynamic interactions
Slovenian: Farmakodinamske interakcije
English: Oral anticoagulants: In subjects stabilised on chronic warfarin therapy, the administration of etoricoxib 120 mg daily was associated with an approximate 13% increase in prothrombin time International Normalised Ratio (INR).
Slovenian: Peroralni antikoagulanti: Pri bolnikih, stabiliziranih na kronični terapiji z varfarinom, je bila uporaba etorikoksiba v odmerku 120 mg dnevno povezana s približno 13 % povišanjem protrombinskega časa, izraženega z INR (International Normalised Ratio).
English: Eye disorders: Uncommon: blurred vision.
Slovenian: Očesne bolezni: Občasne: zamegljen vid.
English: Etoricoxib did not inhibit gastric prostaglandin synthesis and had no effect on platelet function.
Slovenian: Etorikoksib ni zaviral tvorbe prostaglandinov v želodcu in ni vplival na delovanje trombocitov.
English: Therefore, special attention should be paid to blood pressure monitoring during treatment with etoricoxib.
Slovenian: Zato mora biti med zdravljenjem z etorikoksibom posebna pozornost namenjena kontroli krvnega tlaka.
English: The pharmacokinetics of etoricoxib are linear across the clinical dose range.
Slovenian: Farmakokinetika etorikoksiba je v območju kliničnih odmerkov linearna.
English: Digoxin: Etoricoxib 120 mg administered once daily for 10 days to healthy volunteers did not alter the steady-state plasma AUC0-24hr or renal elimination of digoxin.
Slovenian: Digoksin: Etorikoksib v odmerku 120 mg, ki so ga 10 dni enkrat na dan jemali zdravi prostovoljci, ni spremenil plazemske AUC0-24 ur digoksina v stanju dinamičnega ravnovesja ali izločanja digoksina skozi ledvice.
English: As with other drugs known to inhibit prostaglandin synthesis, fluid retention, oedema and hypertension have been observed in patients taking etoricoxib.
Slovenian: Tako kot pri drugih zdravilih, ki zavirajo tvorbo prostaglandinov, so tudi pri bolnikih, ki so dobivali etorikoksib, opazili zadrževanje tekočine, edeme in hipertenzijo.
English: Etoricoxib was not teratogenic in reproductive toxicity studies conducted in rats at 15 mg/kg/day (this represents approximately 1.5 times the daily human dose [90 mg] based on systemic exposure).
Slovenian: Etorikoksib ni deloval teratogeno v raziskavah reproduktivne toksičnosti pri podganah, ki so dobivale odmerek 15 mg/kg/dan (kar predstavlja glede na sistemsko izpostavitev približno 1,5-kratni priporočeni dnevni odmerek pri človeku (90 mg)).
English: Uncommon: dysgeusia, insomnia, paresthaesia/hypaesthesia, somnolence.
Slovenian: Občasne: motnje okušanja, nespečnost, parestezija/hipestezija, zaspanost.
English: Hepatic insufficiency: In patients with mild hepatic dysfunction (Child-Pugh score 5-6) a dose of 60 mg once daily should not be exceeded.
Slovenian: Jetrna okvara: Pri bolnikih z blago motnjo delovanja jeter (lestvica po Child-Pughu 5-6) ne smemo prekoračiti odmerka 60 mg enkrat na dan.
English: A study of approximately 7100 osteoarthritis patients compared the gastrointestinal tolerability of etoricoxib 90 mg (1.5 times the recommended OA dose) with diclofenac 150 mg.
Slovenian: V raziskavi s približno 7.100 bolniki z osteoartrozo so primerjali prenašanje etorikoksiba 90 mg (1,5kratni priporočeni odmerek pri OA) in diklofenaka 150 mg v prebavilih.
English: Etoricoxib has not been shown to cause hepatic CYP3A enzyme induction in humans.
Slovenian: Ni se pokazalo, da bi etorikoksib pri ljudeh induciral jetrne encime CYP3A.
English: Antacids: Antacids do not affect the pharmacokinetics of etoricoxib to a clinically relevant extent.
Slovenian: Antacidi: Antacidi ne vplivajo klinično pomembno na farmakokinetiko etorikoksiba.